[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Blood-Brain Barrier Transport Drugs-North America Market Status and Trend Report 2013-2023

February 2018 | 159 pages | ID: B6AB07AB442EN
MIReports Co., Limited

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Report Summary

Blood-Brain Barrier Transport Drugs-North America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Blood-Brain Barrier Transport Drugs industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole North America and Regional Market Size of Blood-Brain Barrier Transport Drugs 2013-2017, and development forecast 2018-2023
Main market players of Blood-Brain Barrier Transport Drugs in North America, with company and product introduction, position in the Blood-Brain Barrier Transport Drugs market
Market status and development trend of Blood-Brain Barrier Transport Drugs by types and applications
Cost and profit status of Blood-Brain Barrier Transport Drugs, and marketing status
Market growth drivers and challenges

The report segments the North America Blood-Brain Barrier Transport Drugs market as:

North America Blood-Brain Barrier Transport Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

United States
Canada
Mexico

North America Blood-Brain Barrier Transport Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Carrier-mediated Transport
Receptor-mediated Transport
Absorptive-mediated Transport
Active Efflux Transport
Others

North America Blood-Brain Barrier Transport Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Alzheimer's Disease
Epilepsy
Parkinson's Disease
Multiple Sclerosis
Hunter's Syndrome
Brain Cancer
Others

North America Blood-Brain Barrier Transport Drugs Market: Players Segment Analysis (Company and Product introduction, Blood-Brain Barrier Transport Drugs Sales Volume, Revenue, Price and Gross Margin):

Cyclenium
BioAdvance
EIP Pharma
Bioasis
Immune Pharmaceuticals
AZ Therapies
Palobiofarma
Bach Pharma
BrainsGate
CarThera
Dainippon Sumitomo Pharma
Fluorinov Pharma
Fondazione Telethon
Minoryx
NewGen Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

CHAPTER 1 OVERVIEW OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

1.1 Definition of Blood-Brain Barrier Transport Drugs in This Report
1.2 Commercial Types of Blood-Brain Barrier Transport Drugs
  1.2.1 Carrier-mediated Transport
  1.2.2 Receptor-mediated Transport
  1.2.3 Absorptive-mediated Transport
  1.2.4 Active Efflux Transport
  1.2.5 Others
1.3 Downstream Application of Blood-Brain Barrier Transport Drugs
  1.3.1 Alzheimer's Disease
  1.3.2 Epilepsy
  1.3.3 Parkinson's Disease
  1.3.4 Multiple Sclerosis
  1.3.5 Hunter's Syndrome
  1.3.6 Brain Cancer
  1.3.7 Others
1.4 Development History of Blood-Brain Barrier Transport Drugs
1.5 Market Status and Trend of Blood-Brain Barrier Transport Drugs 2013-2023
  1.5.1 North America Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023
  1.5.2 Regional Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023

CHAPTER 2 NORTH AMERICA MARKET STATUS AND FORECAST BY REGIONS

2.1 Market Status of Blood-Brain Barrier Transport Drugs in North America 2013-2017
2.2 Consumption Market of Blood-Brain Barrier Transport Drugs in North America by Regions
  2.2.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in North America by Regions
  2.2.2 Revenue of Blood-Brain Barrier Transport Drugs in North America by Regions
2.3 Market Analysis of Blood-Brain Barrier Transport Drugs in North America by Regions
  2.3.1 Market Analysis of Blood-Brain Barrier Transport Drugs in United States 2013-2017
  2.3.2 Market Analysis of Blood-Brain Barrier Transport Drugs in Canada 2013-2017
  2.3.3 Market Analysis of Blood-Brain Barrier Transport Drugs in Mexico 2013-2017
2.4 Market Development Forecast of Blood-Brain Barrier Transport Drugs in North America 2018-2023
  2.4.1 Market Development Forecast of Blood-Brain Barrier Transport Drugs in North America 2018-2023
  2.4.2 Market Development Forecast of Blood-Brain Barrier Transport Drugs by Regions 2018-2023

CHAPTER 3 NORTH AMERICA MARKET STATUS AND FORECAST BY TYPES

3.1 Whole North America Market Status by Types
  3.1.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in North America by Types
  3.1.2 Revenue of Blood-Brain Barrier Transport Drugs in North America by Types
3.2 North America Market Status by Types in Major Countries
  3.2.1 Market Status by Types in United States
  3.2.2 Market Status by Types in Canada
  3.2.3 Market Status by Types in Mexico
3.3 Market Forecast of Blood-Brain Barrier Transport Drugs in North America by Types

CHAPTER 4 NORTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Blood-Brain Barrier Transport Drugs in North America by Downstream Industry
4.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Major Countries
  4.2.1 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in United States
  4.2.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Canada
  4.2.3 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Mexico
4.3 Market Forecast of Blood-Brain Barrier Transport Drugs in North America by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

5.1 North America Economy Situation and Trend Overview
5.2 Blood-Brain Barrier Transport Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN NORTH AMERICA

6.1 Sales Volume of Blood-Brain Barrier Transport Drugs in North America by Major Players
6.2 Revenue of Blood-Brain Barrier Transport Drugs in North America by Major Players
6.3 Basic Information of Blood-Brain Barrier Transport Drugs by Major Players
  6.3.1 Headquarters Location and Established Time of Blood-Brain Barrier Transport Drugs Major Players
  6.3.2 Employees and Revenue Level of Blood-Brain Barrier Transport Drugs Major Players
6.4 Market Competition News and Trend
  6.4.1 Merger, Consolidation or Acquisition News
  6.4.2 Investment or Disinvestment News
  6.4.3 New Product Development and Launch

CHAPTER 7 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Cyclenium
  7.1.1 Company profile
  7.1.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.1.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Cyclenium
7.2 BioAdvance
  7.2.1 Company profile
  7.2.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.2.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BioAdvance
7.3 EIP Pharma
  7.3.1 Company profile
  7.3.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.3.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of EIP Pharma
7.4 Bioasis
  7.4.1 Company profile
  7.4.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.4.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bioasis
7.5 Immune Pharmaceuticals
  7.5.1 Company profile
  7.5.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.5.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Immune Pharmaceuticals
7.6 AZ Therapies
  7.6.1 Company profile
  7.6.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.6.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of AZ Therapies
7.7 Palobiofarma
  7.7.1 Company profile
  7.7.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.7.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Palobiofarma
7.8 Bach Pharma
  7.8.1 Company profile
  7.8.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.8.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bach Pharma
7.9 BrainsGate
  7.9.1 Company profile
  7.9.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.9.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BrainsGate
7.10 CarThera
  7.10.1 Company profile
  7.10.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.10.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of CarThera
7.11 Dainippon Sumitomo Pharma
  7.11.1 Company profile
  7.11.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.11.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Dainippon Sumitomo Pharma
7.12 Fluorinov Pharma
  7.12.1 Company profile
  7.12.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.12.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fluorinov Pharma
7.13 Fondazione Telethon
  7.13.1 Company profile
  7.13.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.13.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fondazione Telethon
7.14 Minoryx
  7.14.1 Company profile
  7.14.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.14.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Minoryx
7.15 NewGen Therapeutics
  7.15.1 Company profile
  7.15.2 Representative Blood-Brain Barrier Transport Drugs Product
  7.15.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of NewGen Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

8.1 Industry Chain of Blood-Brain Barrier Transport Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

9.1 Cost Structure Analysis of Blood-Brain Barrier Transport Drugs
9.2 Raw Materials Cost Analysis of Blood-Brain Barrier Transport Drugs
9.3 Labor Cost Analysis of Blood-Brain Barrier Transport Drugs
9.4 Manufacturing Expenses Analysis of Blood-Brain Barrier Transport Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach
  12.1.1 Research Programs/Design
  12.1.2 Market Size Estimation
  12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
  12.2.1 Secondary Sources
  12.2.2 Primary Sources
12.3 Reference


More Publications